EASL Updates: Intercept Says Biomarker Data Bolster OCA’s Case For Fibrosis Benefit

Intercept and Axcella provide updated data on their NASH programs at the International Liver Conference, while CymaBay offers the full dataset for seladelpar in PBC.

DATA_Puzzle Piece_186976547_1200.jpg
Companies presented new data in NASH and PBC at EASL 2020

More from Clinical Trials

More from R&D